Inventor
QUERBES WILLIAM
US37 patents
⚠️ This page may combine multiple inventors who share the name “QUERBES WILLIAM”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
ALNYLAM PHARMACEUTICALS INC
34 patentsUS10337010B2Jul 2, 2019
Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC17 citations98
US9771591B2Sep 26, 2017
Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC22 citations98
US9322018B2Apr 26, 2016
Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC36 citations98
US11525138B2Dec 13, 2022
Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC7 citations94
US11332743B2May 17, 2022
Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC6 citations94
US11306316B2Apr 19, 2022
Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC6 citations94
US11306315B2Apr 19, 2022
Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC6 citations94
US11306314B2Apr 19, 2022
Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC6 citations94
US10570393B2Feb 25, 2020
Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC17 citations94
US10557139B2Feb 11, 2020
Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC15 citations94
US10550390B2Feb 4, 2020
Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC15 citations94
US11130953B2Sep 28, 2021
Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC8 citations92
US9133461B2Sep 15, 2015
Compositions and methods for inhibiting expression of the ALAS1 gene
ALNYLAM PHARMACEUTICALS INC19 citations92
US11866709B2Jan 9, 2024
Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC3 citations86
US11840692B2Dec 12, 2023
Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC3 citations84
US11834662B2Dec 5, 2023
Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC3 citations84
US11198872B2Dec 14, 2021
Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC6 citations84
US11142766B2Oct 12, 2021
Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC4 citations84
US11034958B2Jun 15, 2021
Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC7 citations84
US10934545B2Mar 2, 2021
Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC6 citations84
US10407679B2Sep 10, 2019
Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC5 citations84
US10125369B2Nov 13, 2018
PCSK9 iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC9 citations84
US9631193B2Apr 25, 2017
Compositions and methods for inhibiting expression of the ALAS1 gene
ALNYLAM PHARMACEUTICALS INC8 citations83
US12467051B2Nov 11, 2025
Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC0 citations73
US11408001B1Aug 9, 2022
Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC1 citations73
US10478500B2Nov 19, 2019
Compositions and methods for inhibition of HAO1 (Hydroxyacid Oxidase 1 (Glycolate Oxidase)) gene expression
ALNYLAM PHARMACEUTICALS INC4 citations72
US10400239B2Sep 3, 2019
Compositions and methods for inhibiting expression of the ALAS1 gene
ALNYLAM PHARMACEUTICALS INC3 citations72
US10125364B2Nov 13, 2018
Compositions and methods for inhibiting expression of the ALAS1 gene
ALNYLAM PHARMACEUTICALS INC2 citations72
US10119143B2Nov 6, 2018
Compositions and methods for inhibiting expression of the ALAS1 gene
ALNYLAM PHARMACEUTICALS INC3 citations72
US12492401B2Dec 9, 2025
Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC0 citations62
US12460206B2Nov 4, 2025
PCSK9 iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC0 citations62
US11028392B2Jun 8, 2021
Compositions and methods for inhibiting expression of the ALAS1 gene
ALNYLAM PHARMACEUTICALS INC1 citations62
US11446380B2Sep 20, 2022
Compositions and methods for inhibition of HAO1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression
ALNYLAM PHARMACEUTICALS INC0 citations61
US10233452B2Mar 19, 2019
Compositions and methods for increasing erythropoietin (EPO) production
ALNYLAM PHARMACEUTICALS INC0 citations51